Sakarya Tıp Dergisi (Jun 2021)

Treatment Cost Analysis Study In Patients with Atrial Fibrillation Using Warfarin or New Generation Oral Anticoagulant

  • Altuğ Ösken,
  • Aydın Kant,
  • Ercan Aydın,
  • Selcuk Yaylacı,
  • Salih Şahinkuş

DOI
https://doi.org/10.31832/smj.844292
Journal volume & issue
Vol. 11, no. 2
pp. 322 – 327

Abstract

Read online

Objective:We compared the cost analysis of warfarin and new-generation oral anticoagulant (NOAC) treatment in patients with atrial fibrillation. Materials and Methods:Four hundred and ninety-four patients diagnosed with atrial fibrillation at the cardiology outpatient clinic (OC) and using warfarin or NOAC therapy were retrospectively included in the study.Comparison of the total cost of OC and examination fees paid by the social security institution; Fees related to hospitalizations due to hemorrhage caused by anticoagulants and anticoagulant drug cost were compared. Results: In the study group, 18.8% of the anticoagulant drug users were using warfarin, and 81.2% were using NOACs. The average number of admission to OC is more prevalent in patients using warfarin. No statistical difference was observed in gender between patients, but patients using NOAC had a higher mean age (p

Keywords